Schelling Chris 4
4 · Acer Therapeutics Inc. · Filed Sep 21, 2017
Insider Transaction Report
Form 4
Schelling Chris
DirectorPRESIDENT AND CEO10% Owner
Transactions
- Other
Common Stock
[F1]2017-09-19+1,750,000→ 1,750,000 total
Footnotes (1)
- [F1]Received in connection with the Issuer's business combination (the "Merger") with what was then known as "Acer Therapeutics Inc." ("Private Acer") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated June 30, 2017 among the Issuer, Opexa Merger Sub, Inc. and Private Acer, in exchange for 1,750,000 shares of common stock of Private Acer.
Signature
/s/ Daniel S. Clevenger, Attorney-in-Fact for Chris Schelling|2017-09-21